Combinations for the treatment of rheumatoid arithritis
OwnerJason Fong, Edward Jost-Price +5inventors
InventorsJason Fong, Edward Jost-Price, Curtis Keith, Palaniyandi Manivasakam, Grant Zimmermann, Robyn Sackeyfio, Grant Zimmermann
Life of this patent
Estimating the term…
Abstract
The invention features a method for treating a patient diagnosed with rheumatoid arthitis by systemically administering an azole and a steroid to the patient. The invention also features a pharmaceutical composition containing an azole and a steroid for the treatment of rheumatoid arthritis.
Claims20
1-32. (canceled)
A method for treating a patient diagnosed with or at risk for developing rheumatoid arthritis, said method comprising administering to the patient an azole and a steroid, wherein the azole and steroid are systemically administered simultaneously or within 14 days of each other, in amounts sufficient to treat said patient.
A method for treating a patient diagnosed with or at risk for developing rheumatoid arthritis, said method comprising administering to said patient:
- a) a first compound selected from sulconazole, miconazole, clotrimazole, oxiconazole, butocontazole, tioconazole, econazole, and ketoconazole, or itrazonazole, fluconazole, voriconazole, posaconazole, ravuconazole, and terconazole;
- and
- b) a second compound selected from dexamethasone, hydrocortisone, methylprednisolone, prednisone, triamcinolone, and diflorasone;
- wherein said first and second compounds are administered simultaneously or within 14 days of each other, and wherein said first and second compounds are administered in amounts sufficient to treat rheumatoid arthritis in said patient.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an azole and a steroid, wherein said azole and said steroid are present in an amount that, when systemically administered to a patient, inhibit or reduce the symptoms of rheumatoid arthritis;
- and wherein said azole is not effective as an anti-fungal agent.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an azole and a steroid, wherein said azole is in amounts that are not effective as an antifungal agent.
Dependencies are inferred from the claim text.